35th Anniversary Special: Reader Views on Changes in Pharmaceutical Manufacturing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

35th Anniversary Special: Reader Views on Changes in Pharmaceutical Manufacturing
Readers point to quality by design as having a significant influence on manufacturing and drug development during the past decade.

Pharmaceutical Technology
Volume 36, Issue 7, pp. 59-60

To gain a perspective on what have been the most significant changes affecting pharmaceutical development and manufacturing, Pharmaceutical Technology conducted a series of reader polls between December 2011 and May 2012 that asked our readers what they regarded as the most important changes affecting drug-substance and drug-product development and manufacturing during the past 10 years. The polls were directed in five main areas: small-molecule API manufacturing, biologic-based API manufacturing, solid dosage/oral drug delivery, sterile manufacturing, and analytical methods development and instrumentation (see Figures 1–5). Although individual technological advances were cited, an important theme throughout all the polls was the importance of quality by design (QbD).

The importance of quality by design

QbD came into prominence a decade ago when FDA announced a significant new initiative in August 2002, Pharmaceutical Current Good Manufacturing Practices (CGMPs) for the 21st Century (1). The initiative was intended to modernize FDA's regulation of pharmaceutical quality for drugs and select human biological products such as vaccines. The initiative evaluated the pharmaceutical as well as the chemistry, manufacturing, and controls (CMC) regulatory programs with the following specific goals:

  • Encourage adoption of new technological advances
  • Facilitate application of modern quality management techniques, including quality systems, to pharmaceutical production and quality assurance
  • Encourage implementation of risk-based approaches
  • Ensure that regulatory review, compliance, and inspection policies are based on modern pharmaceutical science
  • Enhance the consistency and coordination of FDA's drug-quality regulatory programs, in part, by further integrating enhanced quality-systems approaches (1).

The science- and risk-based approach to pharmaceutical manufacturing that underpins quality by design has been furthered by subsequent guidance from FDA, EMA, and the International Conference on Harmonization. It is not surprising, therefore, that QbD was cited as a significant factor in reader polls.

Drug-substance manufacturing

Figure 1: What is the most important change that has influenced chemical API manufacturing during the past 10 years?
When asked what was the most important change that has influenced chemical API development and manufacturing during the past 10 years, 61% of respondents cited QbD (see Figure 1). The significance of QbD far exceeded any single technological advancement in chemical API manufacturing, including microreactors, chemocatalysis, and biocatalysis.

Figure 2: What has been the most significant development in biologics-based drug development over the past 10 years?
Readers also cited QbD as the most important change in biologic-based API manufacturing (see Figure 2) although its importance was more evenly matched with specific technology gains. Thirty percent cited QbD as the most significant change in biologic-based API manufacturing. Advancement of single-use technologies closely followed at 28%, and then improvements in upstream and downstream processing, each cited by 21% of readers polled.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here